Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

5.150 -0.110 (-2.09%)
Official Closing Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
From CEL-SCI Corporation
Via Business Wire
News headline image
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
From CEL-SCI Corporation
Via Business Wire
News headline image
CVM Stock Earnings: CEL-SCI Reported Results for Q2 2024 ↗
CEL-SCI just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Why CEL-SCI Corporation (CVM) Shares Are Diving ↗
CEL-SCI Corporation shares are trading lower by 13.9% Friday morning. The company priced an offering of 3.875 million shares. 
Via Benzinga
News headline image
CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023 ↗
CEL-SCI just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why CEL-SCI (CVM) Shares Are Trading Higher ↗
CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy. 
Via Benzinga
News headline image
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering
Via Investor Brand Network
News headline image
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
From CEL-SCI Corporation
Via Business Wire
News headline image
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
From CEL-SCI Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Cancer Focused CEL-SCI Stock Trading Higher Today? ↗
CEL-SCI Corporation (AMEX: CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the... 
Via Benzinga
News headline image
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20... 
Via Benzinga
News headline image
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.